Together, these results demonstrate that dual targeting of HIF1α and NT5E in EAC cells not only impacts tumor cell viability but also disrupts key extracellular pathways driving immune evasion, angiogenesis, and metastatic potential, underscoring the multifaceted therapeutic potential of this combinatorial approach in esophageal adenocarcinoma. Here, NT5E is linked to neoplasm.